As healthcare reform falters, the biotech industry awaits the fate of biosimilars and tax credits. Jeff Fox reports.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, J. One year in—Obama's biotech scorecard. Nat Biotechnol 28, 193–196 (2010). https://doi.org/10.1038/nbt0310-193
Issue Date:
DOI: https://doi.org/10.1038/nbt0310-193
- Springer Nature America, Inc.